Cargando…
Are payers treating orphan drugs differently?
BACKGROUND: Some orphan drugs can cost hundreds of thousands of dollars annually per patient. As a result, payer sensitivity to the cost of orphan drugs is rising, particularly in light of increased numbers of new launches in recent years. In this article, we examine payer coverage in the United Sta...
Autores principales: | Cohen, Joshua P., Felix, Abigail |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Co-Action Publishing
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865792/ https://www.ncbi.nlm.nih.gov/pubmed/27226840 http://dx.doi.org/10.3402/jmahp.v2.23513 |
Ejemplares similares
-
Meeting the affordability challenges posed by orphan drugs: a survey of payers, providers, and employers
por: Lopata, Erin, et al.
Publicado: (2021) -
Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe
por: Medic, Goran, et al.
Publicado: (2017) -
Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
por: Hughes-Wilson, Wills, et al.
Publicado: (2012) -
Orphans in the Market: The History of Orphan Drug Policy
por: Mikami, Koichi
Publicado: (2019) -
Variation in Private Payer Coverage of Rheumatoid Arthritis Drugs
por: Chambers, James D., et al.
Publicado: (2016)